Loading
A phase 3 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma is a phase 3 interventional study registered as NCT04712643 by Hoffmann-La Roche, with 342 participants enrolled, started 2021-03-12 and due to reach its primary completion in 2029-02-01. Interventions recorded: Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE). Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Atezolizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Roche / Genentech, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Atezolizumab, Bevacizumab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Atezolizumab, Bevacizumab, Immune checkpoint inhibitors.
Shares Roche / Genentech, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.